keyword
https://read.qxmd.com/read/38429498/potential-therapeutics-for-effort-related-motivational-dysfunction-assessing-novel-atypical-dopamine-transport-inhibitors
#1
JOURNAL ARTICLE
Alev Ecevitoglu, Nicolette Meka, Renee A Rotolo, Gayle A Edelstein, Sonya Srinath, Kathryn R Beard, Carla Carratala-Ros, Rose E Presby, Jianjing Cao, Amarachi Okorom, Amy H Newman, Mercè Correa, John D Salamone
People with depression and other neuropsychiatric disorders can experience motivational dysfunctions such as fatigue and anergia, which involve reduced exertion of effort in goal-directed activity. To model effort-related motivational dysfunction, effort-based choice tasks can be used, in which rats can select between obtaining a preferred reinforcer by high exertion of effort vs. a low effort/less preferred option. Preclinical data indicate that dopamine transport (DAT) inhibitors can reverse pharmacologically-induced low-effort biases and increase selection of high-effort options in effort-based choice tasks...
March 1, 2024: Neuropsychopharmacology
https://read.qxmd.com/read/38256113/social-interaction-in-adolescent-rats-with-neonatal-ethanol-exposure-impact-of-sex-and-ce-123-a-selective-dopamine-reuptake-inhibitor
#2
JOURNAL ARTICLE
Justyna Socha, Pawel Grochecki, Irena Smaga, Joanna Jastrzębska, Olga Wronikowska-Denysiuk, Marta Marszalek-Grabska, Tymoteusz Slowik, Robert Kotlinski, Małgorzata Filip, Gert Lubec, Jolanta H Kotlinska
Children with fetal alcohol spectrum disorders (FASDs) demonstrate deficits in social functioning that contribute to early withdrawal from school and delinquency, as well as the development of anxiety and depression. Dopamine is involved in reward, motivation, and social behavior. Thus, we evaluated whether neonatal ethanol exposure (in an animal model of FASDs) has an impact on social recognition memory using the three-chamber social novelty discrimination test during early and middle adolescence in male and female rats, and whether the modafinil analog, the novel atypical dopamine reuptake inhibitor CE-123, can modify this effect...
January 15, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/37315143/not-so-smart-smart-drugs-increase-the-level-but-decrease-the-quality-of-cognitive-effort
#3
JOURNAL ARTICLE
Elizabeth Bowman, David Coghill, Carsten Murawski, Peter Bossaerts
The efficacy of pharmaceutical cognitive enhancers in everyday complex tasks remains to be established. Using the knapsack optimization problem as a stylized representation of difficulty in tasks encountered in daily life, we discover that methylphenidate, dextroamphetamine, and modafinil cause knapsack value attained in the task to diminish significantly compared to placebo, even if the chance of finding the optimal solution (~50%) is not reduced significantly. Effort (decision time and number of steps taken to find a solution) increases significantly, but productivity (quality of effort) decreases significantly...
June 16, 2023: Science Advances
https://read.qxmd.com/read/35883437/a-novel-and-selective-dopamine-transporter-inhibitor-s-mk-26-promotes-hippocampal-synaptic-plasticity-and-restores-effort-related-motivational-dysfunctions
#4
JOURNAL ARTICLE
Shima Kouhnavardi, Alev Ecevitoglu, Vladimir Dragačević, Fabrizio Sanna, Edgar Arias-Sandoval, Predrag Kalaba, Michael Kirchhofer, Jana Lubec, Marco Niello, Marion Holy, Martin Zehl, Matthias Pillwein, Judith Wackerlig, Rita Murau, Andrea Mohrmann, Kathryn R Beard, Harald H Sitte, Ernst Urban, Claudia Sagheddu, Marco Pistis, Roberto Plasenzotti, John D Salamone, Thierry Langer, Gert Lubec, Francisco J Monje
Dopamine (DA), the most abundant human brain catecholaminergic neurotransmitter, modulates key behavioral and neurological processes in young and senescent brains, including motricity, sleep, attention, emotion, learning and memory, and social and reward-seeking behaviors. The DA transporter (DAT) regulates transsynaptic DA levels, influencing all these processes. Compounds targeting DAT (e.g., cocaine and amphetamines) were historically used to shape mood and cognition, but these substances typically lead to severe negative side effects (tolerance, abuse, addiction, and dependence)...
June 24, 2022: Biomolecules
https://read.qxmd.com/read/35671343/the-2022-ferno-award-address-create-an-efficient-crossover-evaluation-of-addiction-treatment-efficacy
#5
JOURNAL ARTICLE
Kenneth A Perkins
Dozens of drugs have been evaluated in recent decades for initial evidence of efficacy to aid smoking cessation (i.e. "early Phase 2" testing, according to U.S. FDA terminology), with the vast majority failing to show efficacy. Even small randomized clinical trials (RCTs), the most common early Phase 2 tests, are costly undertakings, made more unappealing by their high likelihood of failure. At the same time, another early Phase 2 approach, acute tests of drug effects on surrogate endpoints such as withdrawal or craving severity, are more practical but have little predictive clinical validity...
June 7, 2022: Nicotine & Tobacco Research
https://read.qxmd.com/read/35605783/modafinil-acquires-reinforcing-effects-when-combined-with-citalopram
#6
JOURNAL ARTICLE
Jesús E Yepez, Jorge Juárez
Modafinil (MOD) is a wakefulness promoter used to treat sleep disorders such as narcolepsy and obstructive sleep apnea. Its action mechanism consists in inhibiting dopamine (DAT) and norepinephrine (NET) transporters, but it has no affinity for the serotonin transporter (SERT). Modafinil's addictive potential is not yet clear, but one feature that differentiates it from potentially addictive drugs like cocaine revolves around affinity for SERT. The aims of the present study were to determine whether co-administration of MOD with the selective serotonin reuptake inhibitor citalopram (CIT) can increase MOD's psychostimulant effects on motor activity (MA), verify the effects of subsequent self-administration of MOD mixed with CIT, and document the presence of any symptoms of withdrawal...
June 2022: Pharmacology, Biochemistry, and Behavior
https://read.qxmd.com/read/34907284/cognitive-profiling-and-proteomic-analysis-of-the-modafinil-analogue-s-ce-123-in-experienced-aged-rats
#7
JOURNAL ARTICLE
István Gyertyán, Jana Lubec, Alíz Judit Ernyey, Christopher Gerner, Ferenc Kassai, Predrag Kalaba, Kata Kozma, Iva Cobankovic, Gábor Brenner, Judith Wackerlig, Eva Franschitz, Ernst Urban, Thierry Langer, Jovana Malikovic, Gert Lubec
The lack of novel cognitive enhancer drugs in the clinic highlights the prediction problems of animal assays. The objective of the current study was to test a putative cognitive enhancer in a rodent cognitive test system with improved translational validity and clinical predictivity. Cognitive profiling was complemented with post mortem proteomic analysis. Twenty-seven male Lister Hooded rats (26 months old) having learned several cognitive tasks were subchronically treated with S-CE-123 (CE-123) in a randomized blind experiment...
December 14, 2021: Scientific Reports
https://read.qxmd.com/read/34647651/modafinil-rescues-repeated-morphine-induced-synaptic-and-behavioural-impairments-via-activation-of-d1r-erk-creb-pathway-in-medial-prefrontal-cortex
#8
JOURNAL ARTICLE
Fangyuan Yin, Jinyu Zhang, Ye Lu, Yulei Zhang, Jincen Liu, Cuola Deji, Xiaomeng Qiao, Keqiang Gao, Min Xu, Jianghua Lai, Yunpeng Wang
Long-term opioid abuse causes a variety of long-lasting cognitive impairments such as attention, impulsivity and working memory. These cognitive impairments undermine behavioural treatment for drug abuse and lead to poor treatment retention and outcomes. Modafinil is a wake-promoting drug that shows potential in improving attention and memory in humans and animals. However, modafinil's effect on opioid-induced cognitive impairments remains unclear, and the underlying mechanism is poorly understood. This study showed that repeated morphine administration significantly impairs attention, increases impulsivity and reduces motivation to natural rewards in mice...
January 2022: Addiction Biology
https://read.qxmd.com/read/33917251/neuroenhancement-in-french-and-romanian-university-students-motivations-and-associated-factors
#9
JOURNAL ARTICLE
Irina Brumboiu, Alessandro Porrovecchio, Thierry Peze, Remy Hurdiel, Irina Cazacu, Cristina Mogosan, Joel Ladner, Marie-Pierre Tavolacci
This cross-sectional study aimed to determine the use of neuroenhancers, the motivations and factors associated with their use in French and Romanian university students. Students from two universities in France (Rouen and Opal Coast University) and one in Romania (Cluj-Napoca) were asked to complete a self-administered anonymous questionnaire, either online or on paper, about the use of three different categories of substance: Prescription drugs (methylphenidate, modafinil, and beta-blockers), drugs of abuse (alcohol, cannabis, cocaine, and amphetamines), and soft enhancers (coffee, vitamins, caffeine tablets, and energy drinks)...
April 7, 2021: International Journal of Environmental Research and Public Health
https://read.qxmd.com/read/33802176/the-use-and-impact-of-cognitive-enhancers-among-university-students-a-systematic-review
#10
REVIEW
Safia Sharif, Amira Guirguis, Suzanne Fergus, Fabrizio Schifano
INTRODUCTION: Cognitive enhancers (CEs), also known as "smart drugs", "study aids" or "nootropics" are a cause of concern. Recent research studies investigated the use of CEs being taken as study aids by university students. This manuscript provides an overview of popular CEs, focusing on a range of drugs/substances (e.g., prescription CEs including amphetamine salt mixtures, methylphenidate, modafinil and piracetam; and non-prescription CEs including caffeine, cobalamin (vitamin B12), guarana, pyridoxine (vitamin B6) and vinpocetine) that have emerged as being misused...
March 10, 2021: Brain Sciences
https://read.qxmd.com/read/33519929/pharmacological-neuroenhancement-current-aspects-of-categorization-epidemiology-pharmacology-drug-development-ethics-and-future-perspectives
#11
REVIEW
Johanna Daubner, Muhammad Imran Arshaad, Christina Henseler, Jürgen Hescheler, Dan Ehninger, Karl Broich, Oliver Rawashdeh, Anna Papazoglou, Marco Weiergräber
Recent pharmacoepidemiologic studies suggest that pharmacological neuroenhancement (pNE) and mood enhancement are globally expanding phenomena with distinctly different regional characteristics. Sociocultural and regulatory aspects, as well as health policies, play a central role in addition to medical care and prescription practices. The users mainly display self-involved motivations related to cognitive enhancement, emotional stability, and adaptivity. Natural stimulants, as well as drugs, represent substance abuse groups...
2021: Neural Plasticity
https://read.qxmd.com/read/33272772/rethinking-enhancement-substance-use-a-critical-discourse-studies-approach
#12
JOURNAL ARTICLE
Rebecca Askew, Lisa Williams
BACKGROUND: We draw on both interdisciplinary enhancement substance use research and critical drug studies scholarship to reconceptualise enhancement substance use. Our critical discourse approach illuminates how a variety of substances are positioned as tools for self-improvement. In reconceptualising enhancement substance use, we ask what different substances can be positioned as providing enhancement? How are they positioned as tools for achieving enhancement or self-improvement goals? What discursive repertoires are employed to achieve these aims? METHODS: Forty interviews were conducted with people who use substances, such as ayahuasca, psilocybin, cocaine, alcohol, nootropics and non-prescription pharmaceuticals, including Adderall and modafinil...
September 2021: International Journal on Drug Policy
https://read.qxmd.com/read/32770257/behavioral-and-dopamine-transporter-binding-properties-of-the-modafinil-analog-s-s-ce-158-reversal-of-the-motivational-effects-of-tetrabenazine-and-enhancement-of-progressive-ratio-responding
#13
JOURNAL ARTICLE
Renee A Rotolo, Predrag Kalaba, Vladimir Dragacevic, Rose E Presby, Julia Neri, Emily Robertson, Jen-Hau Yang, Merce Correa, Vasiliy Bakulev, Natalia N Volkova, Christian Pifl, Gert Lubec, John D Salamone
RATIONALE: Atypical dopamine (DA) transport blockers such as modafinil and its analogs may be useful for treating motivational symptoms of depression and other disorders. Previous research has shown that the DA depleting agent tetrabenazine can reliably induce motivational deficits in rats, as evidenced by a shift towards a low-effort bias in effort-based choice tasks. This is consistent with human studies showing that people with major depression show a bias towards low-effort activities...
November 2020: Psychopharmacology
https://read.qxmd.com/read/32597132/in-search-of-optimal-psychoactivation-stimulants-as-cognitive-performance-enhancers
#14
REVIEW
Emil Bartosz Rozenek, Monika Górska, Karolina Wilczyńska, Napoleon Waszkiewicz
An increasing number of people, students in particular, seek substances that improve their cognitive functioning. The most popular group of pharmacological cognitive enhancers (PCEs) are stimulants. Available studies suggest a small beneficial effect of methylphenidate and amphetamine on memory, executive functions, and processing speed. However small, this effect can make the difference between success and failure. In recent years, research has focused on the additional beneficial effect on the emotional state, increased motivation, and placebo-induced cognitive enhancement...
September 1, 2019: Arhiv za Higijenu Rada i Toksikologiju
https://read.qxmd.com/read/32443397/neurophysiological-and-neurochemical-effects-of-the-putative-cognitive-enhancer-s-ce-123-on-mesocorticolimbic-dopamine-system
#15
JOURNAL ARTICLE
Claudia Sagheddu, Nicholas Pintori, Predrag Kalaba, Vladimir Dragačević, Gessica Piras, Jana Lubec, Nicola Simola, Maria Antonietta De Luca, Gert Lubec, Marco Pistis
Treatments for cognitive impairments associated with neuropsychiatric disorders, such as attention deficit hyperactivity disorder or narcolepsy, aim at modulating extracellular dopamine levels in the brain. CE-123 (5-((benzhydrylsulfinyl)methyl) thiazole) is a novel modafinil analog with improved specificity and efficacy for dopamine transporter inhibition that improves cognitive and motivational processes in experimental animals. We studied the neuropharmacological and behavioral effects of the S -enantiomer of CE-123 (( S )-CE-123) and R -modafinil in cognitive- and reward-related brain areas of adult male rats...
May 18, 2020: Biomolecules
https://read.qxmd.com/read/32297564/cognitive-enhancement-drug-use-among-resident-physicians-prevalence-and-motivations-for-use-results-from-a-survey
#16
JOURNAL ARTICLE
Dafna Sara Rubin-Kahana, Ziv Rubin-Kahana, Maya Kuperberg, Rafael Stryjer, Dorit Yodashkin-Porat
Background: Non-medical use of prescription drugs for the enhancement of cognitive functioning has gained popularity in recent years, especially among young educated adults. To our knowledge, no previous study investigated this phenomenon among resident physicians. Objective: To analyze cognitive enhancement drugs use motivations and patterns among resident physicians. Methods: A survey and statistical analysis regarding the use of drugs traditionally prescribed for the treatment of Attention Deficit Hyperactivity Disorder: stimulants, amphetamines and modafinil...
2020: Journal of Addictive Diseases
https://read.qxmd.com/read/31507388/operant-assessment-of-dmtp-spatial-working-memory-in-mice
#17
JOURNAL ARTICLE
Jasper Teutsch, Dennis Kätzel
Working memory (WM) is required to bridge the time between the moment of sensory perception and the usage of the acquired information for subsequent actions. Its frequent and pharmacoresistent impairment in mental health disorders urges the development of rodent paradigms through back-translation of human WM tests, ideally avoiding the confounds of alternation-based assays. Here we show, that mice can acquire a delayed-matching-to-position (DMTP) operant spatial WM (SWM) paradigm that is akin to the combined attention and memory (CAM) task previously developed for rats, and that relies on a 5-choice wall [5-CSWM, 5-choice based operant testing of SWM (5-CSWM)]...
2019: Frontiers in Behavioral Neuroscience
https://read.qxmd.com/read/31316379/the-novel-atypical-dopamine-uptake-inhibitor-s-ce-123-partially-reverses-the-effort-related-effects-of-the-dopamine-depleting-agent-tetrabenazine-and-increases-progressive-ratio-responding
#18
JOURNAL ARTICLE
Renee A Rotolo, Vladimir Dragacevic, Predrag Kalaba, Ernst Urban, Martin Zehl, Alexander Roller, Judith Wackerlig, Thierry Langer, Marco Pistis, Maria Antonietta De Luca, Francesca Caria, Rebecca Schwartz, Rose E Presby, Jen-Hau Yang, Shanna Samels, Merce Correa, Gert Lubec, John D Salamone
Animal studies of effort-based choice behavior are being used to model effort-related motivational dysfunctions in humans. With these procedures, animals are offered a choice between high-effort instrumental actions leading to highly valued reinforcers vs. low effort/low reward options. Several previous studies have shown that dopamine (DA) uptake inhibitors, including GBR12909, lisdexamfetamine, methylphenidate, and PRX-14040, can reverse the effort-related effects of the vesicular monoamine transport blocker tetrabenazine, which inhibits DA storage...
2019: Frontiers in Pharmacology
https://read.qxmd.com/read/31173409/effect-of-acute-modafinil-ingestion-on-cognitive-and-physical-performance-following-mental-exertion
#19
RANDOMIZED CONTROLLED TRIAL
Ben Rattray, Kristy Martin, Alex Hewitt, Gabrielle Cooper, Warren McDonald
OBJECTIVE: Modafinil is a psychostimulant that has been shown to enhance cognitive and physical performance. Given its long half-life, it may provide operational advantages if it can improve tolerance to the deleterious effects of prolonged mental exertion. METHODS: Physically active males (n = 13, 23 ± 4 years, peak oxygen consumption 45.3 ± 3.2 ml kg-1  min-1 ) took part in a placebo controlled, double-blind randomised crossover study to investigate if modafinil could improve cognitive and physical performance following a prolonged period of mental exertion...
July 2019: Human Psychopharmacology
https://read.qxmd.com/read/29902691/pharmacological-cognitive-enhancement-among-non-adhd-individuals-a-cross-sectional-study-in-15-countries
#20
COMPARATIVE STUDY
Larissa J Maier, Jason A Ferris, Adam R Winstock
BACKGROUND: Psychoactive substance use aiming at increased performance at work or while studying, usually referred to as pharmacological cognitive enhancement (PCE), has been extensively researched in recent years. While large scale national studies have tried to assess the prevalence of PCE among the general population, cross-cultural comparisons have been hampered by the different definitions and designs included. In addition, the non-medical use of prescription drugs indicated to treat the symptoms of the Attention Deficit Hyperactivity Disorder (ADHD) has been the focus of discussion, yet no study has addressed the association between ADHD rates, prescribing behaviour and PCE yet...
August 2018: International Journal on Drug Policy
keyword
keyword
98336
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.